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Mycobacteria encode ﬁve type VII secretion system (T7SS) or ESX for nutrient acquisition and virulence.
Mycosins are membrane-anchored components of ESX with serine protease activity but an unidentiﬁed
substrate range. Establishing the substrate speciﬁcity of individual mycosins will help to elucidate in-
dividual ESX functions. Mycosin-1 and -3 orthologues from two environmental mycobacterial species,
Mycobacterium smegmatis and Mycobacterium thermoresistibile, have been heterologously produced, but
mycosins from Mycobacterium tuberculosis (Mtb) remain to be studied. Here we describe the successful
production of Mtb mycosin-3 as a ﬁrst step in investigating its structure and function.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pathogenic Gram negative bacteria use a range of secretion
systems to secrete virulence factors or transport the factors into
host cells to manipulate the host immune system [1]. Type VII se-
cretion systems (T7SSs) are restricted to mycobacteria and some
other high GC Gram-positive bacteria [2,3]. Mycobacterium tu-
berculosis (Mtb), the etiological agent of tuberculosis, has ﬁve T7SSs,
denoted as ESX-1 to -5 presumably evolved by gene duplication [4].
ESX-1 and -5 are critical to virulence in pathogenic mycobacteria [5],
and ESX-3 participates in mycobactin-mediated iron acquisition
[6,7]. ESX-5 was recently found to additionally function in nutrient
acquisition [8]. ESX-1, 3 and 5 are correspondingly essential for Mtb
growth in vitro [9,10]. The roles of ESX-2 and -4 are not yet clear. The
close association of ESXs with fundamental biological processes has
resulted in much research interest in T7SS.
Details of T7SS secretion have not been fully elucidated including
the highly conserved mycosin components. Analysing mycosins may
therefore help to unravel their functions. Mycosin-5 was not co-iso-
lated with the central, double membrane spanning complex consist-
ing of EccB, EccC, EccD and EccE, indicating a weak association in vivo
[11]. Mycosins share a conserved catalytic triad of aspartate, histidineB.V. This is an open access article uand serine with subtilisin-like serine proteases [12]. Screening ex-
periments, however, did not identify mycosin substrates [12]. Re-
cently, mycosin-1 (MycP1) was found to cleave EspB twice upon se-
cretion [13] to potentially facilitate its maturation for host target in-
teraction. This is, however, unlikely to be the only mycosin substrate,
as the gene espB is unique to ESX-1. ESX-1 substrate secretion is de-
pendent on mycosin-1 but removing its enzymatic activity un-
expectedly increases secretion [13]. Mycosin-1 may thus ensure Mtb
persistence by balancing immune detection and virulence [13].
Mycosins have an N-terminal secretion signal followed by a
potential “pro-peptide”, a catalytic domain, a proline-rich linker
and a hydrophobic transmembrane region (Fig. 1). While removal
of the “pro-peptide” was originally proposed to be required for
enzymatic activation [12], this was found not to affect its protease
activity [14–16]. In addition, crystal structures of mycosin-1 from
M. smegmatis andM. thermoresistibile and mycosin-3 (MycP3) from
M. smegmatis suggest that the “pro-peptide” wraps around the
catalytic domain possibly to stabilize it. The “pro-peptide” has
hence been renamed the “N-terminal extension region” [14–16].
The MycP1 orthologue ofM. smegmatis inefﬁciently cleaves EspB in
vitro possibly due to other ESX-1 components being absent [14].
However, mycosin-1 orthologues from M. smegmatis and M. ther-
morsistibile are unlikely to be involved in virulence in these sa-
prophytic species despite an amino acid sequence identity of 70%
withMtb protein. Production of recombinant mycosin-1 or -3 from
M. tuberculosis is problematic. Although the role of mycosin-3 re-
mains enigmatic, it is essential to M. tuberculosis survival in vitronder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. The primary structure ofM. tuberculosismycosin-3 (MycP3). Single underline: signal peptide; double underline: N-terminal extension; dashed underline: proline-rich
linker; wave underline: hydrophobic transmembrane region; white on black: catalytic triad, Asp95-His126-Ser342.
Table 1
Primers used to generate the startingM. tuberculosis mycP3 construct (pET-28a construct was not codon-optimized), and eight codon-optimizedmycP3 constructs (Constructs
A to I), Expression hosts and vectors are as listed.
Construct Name Encoded Amino Acid Sequence Expression Host Expression Vector Primer Sequences and Their Restriction Sites
Construct A Ile26-Asn430 E. coli BL21 (DE3) pLysS pET-28a forward: 5′-CCATGGCGATCGGGCCGCCGG-3′ (NcoI)
reverse: 5′-CTCGAGGTTGCGCGGTGTGGTG-3′ (XhoI)
pGEX-6P-1 N/A (restricted directly from the synthetic construct)
Construct B Arg51-Asn430 pET-28a forward: 5′-CCATGGAACGCGGTGCGTGCAG-3′ (NcoI)
Construct A reverse primer
pGEX-6P-1 forward: 5′-GGATCCCGCGGTGCGTGCAG-3′ (BamHI)
Construct A reverse primer
Construct C Gly52-Leu401 pGEX-6P-1 forward: 5′-GGATCCGGTGCATGTAGCG-3′ (BamHI)
reverse: 5′-CTCGAGTCACAGCTGCCAGGTC-3′ (XhoI)
Construct D Ser57-Leu401 pGEX-6P-1 forward: 5′-GGATCCGGTGTTATTCCGG-3′ (BamHI)
Construct C reverse primer
Construct E Gly62-Leu401 pGEX-6P-1 forward: 5′-GGATCCGGTACAGATCCGG-3′ (BamHI)
Construct C reverse primer
Construct F Val67-Leu401 pGEX-6P-1 forward: 5′-GGATCCGTTCCGACCCCGAG-3′ (BamHI)
Construct C reverse primer
Construct G Ser71-Leu401 E. coli Arctic Express and BL21 (DE3)
pLysS
pGEX-6P-1 forward: 5′-GGATCCCAGACCATGCTG-3′ (BamHI)
Construct C reverse primer
pCOLD forward: 5′-CATATGCAGACCATGCTGAATC-3′ (NdeI)
Construct C reverse primer
Construct H Leu77-Leu401 E. coli BL21 (DE3) pLysS pGEX-6P-1 forward: 5′-GGATCCCTGCCAGCAGCATG-3′ (BamHI)
Construct C reverse primer
Construct I Ile24-Leu401 E. coli Origami II and Rosetta gami II pGEX-6P-1 forward: 5′-GGATCCATTGGTCCGCCTGTTG-3′ (BamHI)
Construct C reverse primer
*Underlined sequences are restriction sites as indicated in brackets.
Fig. 2. Disordered region probability plot for Mtb H37Rv MycP3 with a prediction false positive rate of 5%, where the disordered region prediction software DrDOS identiﬁed
two disordered regions, Met1-Pro37 and Pro405-E461.
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In this study, the gene mycP3 from M. tuberculosis H37Rv was
cloned and expressed. Extensive effort was made to optimize the
construct for soluble mycosin-3 production to increase yield and
stability. This report may aid efforts to study mycosin-3 with re-
spect to substrate screening, functional characterization, enzyme
kinetics and crystal structure determination.2. Materials and methods
2.1. Media, plasmids and bacteria strains
Lysogeny broth (LB) was used to culture all Escherichia coli
strains including XL-1 blue (Promega), BL21 (DE3) pLysS (Prome-
ga), Arctic Express (Agilent Technologies), Origami II (Novagen),
and Rosetta gami II (Novagen). E. coli expression vector pGEX-6P-1
Fig. 3. Test expression and solubility test for Construct G expressed in E. coli Arctic Express strain. Protein production level are high in both soluble and insoluble fractions. M:
Protein Marker; E: Empty (bands present overﬂow from other lanes); P: Pellet; S: Supernatant.
Table 2
Sequence identity between mycosin orthologues from Mtb, M. smegmatis, and M. thermoresistibile
SeqA Name Length SeqB Name Length Alignment Score
Msmeg_0083|MycP1 449 M.therm KEK_05522|MycP1 443 78.8
Mtb Rv3883c|MycP1 446 Msmeg_0083|MycP1 449 72.0
Mtb Rv3883c|MycP1 446 M. therm KEK_05522|MycP1 443 71.1
Mtb Rv0291|MycP3 461 Msmeg_0624|MycP3 459 59.0
Msmeg_0624|MycP3 459 M. therm KEK_05522|MycP1 443 44.0
Mtb Rv3883c|MycP1 446 Msmeg_0624|MycP3 459 44.0
Mtb Rv0291|MycP3 461 M. therm KEK_05522|MycP1 443 43.8
Msmeg_0624|MycP3 459 Msmeg_0083|MycP1 449 43.2
Mtb Rv0291|MycP3 461 Msmeg_0083|MycP1 449 42.8
Mtb Rv0291|MycP3 461 Mtb Rv3883c|MycP1 446 42.4
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used to produce mycosin-3 fusion proteins respectively with an
N-terminal glutathione S-transferase (GST)-, an N-terminal His6-,
and a C-terminal His6-tag.
2.2. Cloning of MycP3 constructs
A range of truncated mycP3 constructs were generated by poly-
merase chain reaction (PCR) using speciﬁc primer pairs (Table 1),
Phusion DNA polymerase (ThermoScientiﬁc), and either Mtb H37Rv
gemomic DNA (gift from RobWarren) or codon-optimizedmycP3 gene
(GeneArt) as template. PCR products were ligated into pJET2.1 cloning
vector (ThermoScientiﬁc) using T4 DNA ligase (Promega). The re-
combinant pJET2.1 vector was propagated using E. coli XL-1 Blue strain
and restriction digested to provide an insert for ligation into expres-
sion vectors. The recombinant host-speciﬁc expression vectors were
electroporated into E. coli expression host cells.
2.3. Production and puriﬁcation of MycP3 protein
An overnight 50 mL starter culture was prepared from a single E.
coli transformant colony. An aliquot of the starter culture was trans-
ferred to 1 L LB medium, allowed to grow to mid-log phase
(OD600 nm¼0.6 to 0.8) at 37 °C and induced with 0.1–0.5 mM iso-
propyl β-D-1-thiogalactopyranoside (IPTG) at 16, 25 and 30 °C for 18 h
for test expression. Arctic express and pCOLD transformants were in-
duced with 0.1 mM IPTG at 13 °C and expression continued for 40 h.
For the GST fusion protein puriﬁcation, cultures were harvested
by centrifugation at 3000g at 4 °C for 10 min. The pellet was re-
suspended in phosphate buffered saline (PBS) and sonicated using
a probe sonicator (MSE) at an amplitude of 20 mm for 5 cycles of
30 s with 30 s incubation on ice. The soluble and insoluble frac-
tions of the cell lysate were separated by centrifugation at 14,000gat 4 °C for 45 min. The supernatant was agitated with 2 mL PBS-
equilibrated glutathione agarose beads (ABT) at 4 °C on a roller
mixer for 1 h for fusion protein coupling. The mixture was poured
into a drip column and the ﬂowthrough eluted under gravity. The
column was washed with 20 column volumes (CV) of PBS. The
fusion protein was eluted with elution buffer: 25 mM Tris–HCl, pH
7.4, 150 NaCl, 15 mM reduced glutathione.
For the puriﬁcation of the His6-tagged fusion proteins, the E.
coli cell pellet was resuspended in lysis buffer (25 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 10 mM imidazole) and lysed by a tissue and
cell homogenizer FastPrep-24 (MP Biomedical) at a speed of 6 m/s
for 5 cycles of 30 s alternating with 30 s incubation on ice. The
soluble fraction was separated as described above and the target
protein was coupled to Ni-NTA beads (Qiagen). The beads were
loaded into a drip column and washed with 20 CV wash buffer
(25 mM Tris–HCl, pH 7.4, 150 NaCl, 20 mM imidazole) and eluted
with elution buffer: wash buffer with 250 mM imidazole.3. Results
Identifying the catalytic domain of MycP3 is critical prior to
cloning and production experiments. MycP3 has a signal peptide,
Met1-Ala25, and an N-terminal extension, Ile26-Gln50, N-terminal
of the presumed catalytic domain, Arg51-Leu401, followed by a
linker, Pro402-Asn430, and a transmembrane region, Val431-Glu461
(Fig. 1). Two truncated constructs of mycP3 were ampliﬁed from
Mtb H37Rv genomic DNA and cloned into pET-28a E. coli expres-
sion vector to produce C-terminally His6-tagged fusion protein:
Construct A encoding Ile26-Asn430, lacks the signal peptide and the
transmembrane region. Construct B encodes Arg51-Asn430, which
additionally lacks the “pro-peptide” or “N-terminal extension”.
Neither construct produced sufﬁcient fusion protein in E. coli BL21
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E. coli codon usage differs signiﬁcantly from that of myco-
bacteria [19]. Mtb mycP3 DNA encoding Ile26-Asn430 was corre-
spondingly codon-harmonized for E. coli expression. Correspond-
ing constructs A and B were cloned into plasmid pGEX-6P-1. The
encoded GST MycP3 fusion proteins produced small quantities of
insoluble protein (Figs. S1 and S2 for construct A). Small amounts
of soluble fusion protein proved unstable, prone to rapid proteo-
lysis and precipitation. Chaperone proteins, such as DnaK (69 kDa)
and heat shock chaperonin (60 kDa) were co-produced and iden-
tiﬁed by mass spectrometry (results not shown, service provided
by Central Analytical Facility, Stellenbosch University). Triton
X-100 treatment removed the chaperones. However, MycP3 was
thereupon rapidly degraded (results not shown). Lowering the
expression temperature to 16, 25 and 30 °C and varying IPTG
concentrations from 0.1 to 1 mM did not improve the solubility or
stability of the fusion protein (Fig. S2).
As inherently disordered region (IDR) of the MycP3 fusion
protein may limit its solubility and stability, the protein was ana-
lysed using PrDOS [20]. This identiﬁed Met1-Pro37 and Pro405-E461
as potentially disordered (Fig. 2). The region Pro402 to Glu461 was
excluded from analysis as it encompasses the proline-rich linker
and the C-terminal transmembrane α-helix [12]. A set of MycP3
constructs removing residues Ile26 to Gln50 in steps of ﬁve to six
amino acids was generated: Construct C encodes Gly52-Leu401, D:
Ser57-Leu401, E: Gly62-Leu401, F: Val67-Leu401, G: Ser71-Leu401, and
H: Leu77-Leu401. The six constructs were cloned into pGEX-6P-1 for
GST fusion protein production. Protein production levels for con-
structs C and D were low while those for E to H were higher (Fig.
S3). However, the GST–MycP3 fusion proteins were invariably in-
soluble (Fig. S4). Gene expression at 16, 25 and 30 °C similarly did
not improve the solubility of the resulting protein. Construct G
was selected for further optimization of MycP3 production as the
elimination of a proline/valine-rich portion (Gly52-Pro70) could
improve the yield.
MycP3 contains four cysteines, Cys54, Cys123, Cys205 and Cys249.
As a secreted protein, MycP3 stability could be disulﬁde bond de-
pendent. Construct I, encoding MycP3 Ile26-Leu401 was produced in
E. coli expression strains, Origami II and Rosetta Gami II with
oxidizing cytosol. However, the resulting protein was again in-
soluble (results not shown).
The vector pCOLD and the strain Arctic Express are designed to
increase the solubility of produced protein [21]. The co-production
of pCOLD encoded cold-shock chaperones alongside Construct G
did, again, not increase the protein solubility in both BL21 (DE3)
and Arctic Express cells (Fig. S5). Unexpectedly, though, expression
of Construct G in pGEX-6P-1 vector in Arctic Express produced
signiﬁcant amounts of soluble GST MycP3 Ser71-Leu401 fusion
protein (Fig. 3) that could be cleaved by PreScission Protease
(Roche) to release MycP3 Ser71-Leu401 (Fig. S6).4. Discussion
Production of Mtb proteins in E. coli has repeatedly been found
to be challenging possibly due to its GC rich (465%) genome and a
distinct codon usage. Mtb proteins further incorporate more gly-
cines, alanines, prolines and arginines than E. coli and the organ-
ism also has post-translational modiﬁcation machinery that E. coli
lacks [22]. Although saprophytic M. smegmatis is occasionally
suitable for Mtb protein production, only a handful of successful
cases of protein production have been reported [23].
In this study, a range of mycP3 constructs were generated with
variable truncations and tags. Truncations can eliminate in-
herently disordered regions whereas a soluble tag may increase
the solubility of an attached cargo. Correspondingly, GST–MycP33fusion proteins proved more soluble than His6-tagged counter-
parts. Lower IPTG concentrations and production temperatures
limit heat shock protein production, proteolytic degradation, pro-
tein aggregation and improve protein stability [24]. MycP3 fusion
protein, however, remained insoluble except when produced in
Arctic Express. Although rarely used for Mtb H37Rv protein pro-
duction [23], Arctic Express successfully produced GST-tagged
MycP3 fusion proteins in signiﬁcant quantity at low temperature
despite lacking an N-terminal extension that stabilizes the cata-
lytic domain [14–16].
The crystal structures of three mycosin orthologues from en-
vironmental mycobacterial species with high sequence identity to
Mtb proteins have been solved. This includes MycP1 from M. smeg-
matis and M. thermoresistibile, as well as MycP3 from M. smegmatis
[14–16]. An amino acid sequence alignment [25] of MycP1 and MycP3
from Mtb and M. smegmatis, as well as MycP1 from M. thermo-
resistibile reveals that MycP1 from M. smegmatis and M. thermo-
resistibile are closely related (alignment score: 78.8) whileMtbMycP1
is signiﬁcantly different (alignment score 72.0) (Table 2). MycP3 from
Mtb and M. smegmatis are even more distantly related. A model for
MtbMycP3 was generated using MycP3 fromM. smegmatis and Swiss
Model [26]. The two structures demonstrate no signiﬁcant differ-
ences (Fig. S7). A QMEANZ-score of 1.45 [26], however, indicates
some uncertainty in the model structure. The low sequence align-
ment and QMEANZ-score may indicate a difference in substrate
speciﬁcity especially as ESX-1 is virulence associated in Mtb while it
is essential for DNA transfer in M. smegmatis [27,28]. Investigating
the function of Mtb mycosins thus remain important.
To distinguish the enzyme speciﬁcity of different mycosins is cri-
tical to understand the function of different ESXs. In conclusion, this
study reports the successful attempts at producing soluble MycP3
fromMtb H37Rv. It is hoped that this information may facilitate future
structural and functional studies. Mycosins are evolutionarily only
distantly related to other substilisins implying that they could be at-
tractive drug targets especially as MycP1 regulates secretion and pro-
cesses the secreted virulence factor from ESX-1 whereas MycP3 ap-
pears to be involved in iron or possibly even heme acquisition [29].Author contributions
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